---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002936"
form_type: "8-K/A"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:28:03.287167+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology reports $468.3M cash; runway into H2 2026 unchanged

## Summary
- Preliminary unaudited cash, equivalents, investments, and interest receivable totaled $468.3M as of Dec 31, 2023.
- Cash runway reaffirmed through second half of 2026 based on current operating plan.
- Amendment corrects original 8-K filing item number from 2.01 to 2.02; no other changes.
- Preliminary estimate subject to completion of quarter-end financial close procedures.

## SEC filing metadata
- accession: 0000950170-24-002936
- form_type: 8-K/A
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 2.01, 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024002936/0000950170-24-002936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024002936/cgem-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002936
- JSON: https://secwatch.observer/filing/0000950170-24-002936.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002936.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. updated its as of December 31, 2023 guidance (reaffirmed).
  - Period: as of December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: As of December 31, 2023, the Company's unaudited cash, cash equivalents, investments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Company expects its cash resources to provide runway into the second half of 2026 based on its current operating plan. The Company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024002936/0000950170-24-002936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.